Literature DB >> 2558329

[Comparison of the efficacy of monotherapy with a beta-blocker, a diuretic, and ACE inhibitors in the control of blood pressure during stress].

S C Wu, L Oltrona, M B Secchi, S Mancarella, L Bettazzi, M Civelli, C Sannino, G Loche, G Folli.   

Abstract

In order to compare the efficacy of beta-blocking, diuretics and ACE-inhibiting monotherapy in controlling the blood pressure increase to stress, a study was conducted on 30 subjects (10 treated with atenolol, 10 with hydrochlorothiazide/amiloride combination, 10 with enalapril) with mild or moderate essential hypertension whose resting blood pressures were normalised by therapy. In the 3 groups of subjects blood pressure values at rest, during mental stress, static and dynamic exercise did not significantly differ before antihypertensive therapy. Atenolol and enalapril significantly reduced systolic and diastolic pressure below pretreatment values throughout and immediately after each test, differing from diuretic therapy which did not show any significant reduction in diastolic rises at the peak of hand-grip or in both systolic and diastolic pressures at the highest work-loads during dynamic exercise. In the recovery period of the exercise cycle test diuretics also produced a later normalisation of diastolic pressure. In conclusion, beta-blockers and ACE-inhibitors seem to be more effective than diuretics in the control of the blood pressure response to stress in hypertensive patients, suggesting that these drugs are the first choice treatment of mild to moderate hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558329

Source DB:  PubMed          Journal:  Minerva Cardioangiol        ISSN: 0026-4725            Impact factor:   1.347


  1 in total

1.  Atenolol blunts blood pressure increase during dynamic resistance exercise in hypertensives.

Authors:  Ricardo S Gomides; Luiz A R Costa; Dinoélia R Souza; Andréia C C Queiroz; João R C Fernandes; Kátia C Ortega; Décio Mion Junior; Taís Tinucci; Cláudia L M Forjaz
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.